CRCHUM

New licence provides CHUM access to the ERS CRISPR/Cas9 patent portfolio. DUBLIN and MONTREAL, Oct. 26, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with the CHUM Research Centre ('(CRCHUM),'). This is a non-exclusive licensing agreement granting the CRCHUM research rights to the ERS CRISPR/Cas9 patent portfolio. Dr. Emmanuelle Charpentier, founder of ERS Genomics, received the 2020 Nobel Prize for the discovery of CRISPR/Cas9. As a direct outcome, the ERS patent portfolio is the definitive collection of proprietary rights to this gene editing technology. Continue Reading Eric Rhodes, CEO ERS Genomics CHUM Research Centre logo The CHUM Research Centre is the largest research centre in the field of biomedical sciences and health care at the University of Montreal. It is one of the largest and most modern in Canada. "With the acquisition of this new license, the CHUM Research Centre has now both the technological capacity and the legal ability to carry out research projects with commercial partners," explained Vincent Poitout, Director of Research at the Centre hospitalier de l'Université de Montréal (CHUM) and Scientific director of the CRCHUM. Eric Rhodes, CEO, ERS Genomics was equally enthusiastic about the new agreement: 'Canada's role in the biotechnology landscape has been gaining prominence on a global scale. Particularly, the bio-economy is experiencing rapid growth with Montreal standing out as a noteworthy hub. Aligning perfectly with our corporate vision, this licensing agreement with CRCHUM in Canada signifies a crucial step towards expanding the use of CRISPR/Cas9 globally.' Financial details of the agreement are not being disclosed. About the CRCHUM The CHUM Research Centre (CRCHUM) is one of North America's leading hospital research centres. It strives to improve the health of adults through a continuum of research spanning disciplines such as basic science, clinical research and population health. More than 2,150 people work at the CRCHUM, including nearly 500 researchers and nearly 650 students and postdoctoral fellows. For additional information, please visit Contact: Andrée-Anne Toussaint [email protected] About ERS Genomics ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. ERS holds over 100 patents worldwide. For additional information, please visit Media contact: Cillian McGorman, +353 86 396 8499, [email protected] Photo - Logo - Logo - SOURCE ERS Genomics

VANCOUVER, BC, March 22, 2023 /PRNewswire/ - CuePath Innovation, a provider of medication adherence solutions for the home healthcare market, announced today that it has been selected to provide its medication compliance monitoring system for a clinical trial led by the Centre Hospitalier de l'Université de Montréal Research Centre (CRCHUM). This will be the first clinical trial in Canada to use Cuepath for automated medication compliance monitoring in the research protocol. The clinical trial is funded by the Canadian Institutes of Health Research and is scheduled to commence in June 2023. The clinical trial will study a medication and a psychosocial intervention, alone and in combination, for people who live with methamphetamine use disorder. Clinical trials typically rely on participant self-reporting or daily witnessed ingestion at pharmacy to record medication compliance. CuePath brings its automated medication compliance monitoring and analysis to the clinical trial, so researchers can accurately monitor and collect detailed data on medication intake, enhancing patient safety and allowing better evidence overall for treatment adherence. CuePath CEO, Ken Piaggio, stated, "This will be the first clinical trial in Canada to use CuePath's automated medication adherence monitoring." Piaggio continued, "We expect this to be the first of many more clinical trials in North America that employ our innovation technology. We are excited to work with CRCHUM and its research partners to improve the healthcare of Canadians." About Centre Hospitalier de l'Université de Montréal Research Centre The Centre Hospitalier de l'Universite de Montreal Research Centre is one of North America's leading hospital research centres. It strives to improve the health of adults through a continuum of research spanning disciplines such a basic science, clinical research and population health. More than 2,150 people work at CRCHUM, including nearly 500 researchers and 650 students and postdoctoral fellows. About CuePath CuePath Innovation™ is a healthcare technology company focused on improving medication adherence of adults with chronic conditions. Its mission is to bring peace of mind to caregivers by improving the quality of life of its customers. CuePath couples its Medication Adherence as a Service (MAaaS) platform with its outcomes-based virtual care service to resolve patient non-adherence. It partners with leading home care agencies and pharmacies to deliver its innovative and effective subscription service. SOURCE CuePath Innovation